Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Myeloid Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.myeloidtx.com/
Year Founded: 2019
Status: Private
BioCentury | Jul 5, 2024
Product Development
LNP innovation: tissue specificity, aided by AI
How LNP companies delivering nucleic acids are cracking the tissue tropism problem, and finding freedom to operate
BioCentury | May 18, 2023
Regulation
May 18 Quick Takes: Vaccines panel backs Pfizer RSV vaccine
Plus: Pressure mounts on CMS over Alzheimer’s therapies, financing updates for Coherent, Myeloid, Cabaletta, RedCloud, CytoCares, and more
BioCentury | Dec 7, 2022
Management Tracks
Bill Meury to lead Karuna
Plus: Moore to head Roche Diagnostics North America division, and updates from Agios, Verge, LifeMine and more
BioCentury | Jun 24, 2022
Data Byte
CAR T cells headline HER2 cell therapy pipeline
CAR T cells are the most popular strategy to hit the solid tumor-selective target, but companies are using at least five other methods
BioCentury | Mar 25, 2022
Data Byte
The TREM1 pipeline gets one more therapy
Celsius throws its hat in the ring for a first-in-class IBD treatment
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Feb 12, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging cell therapy companies
The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing
BioCentury | Dec 11, 2021
Finance
More dry powder for Newpath’s company creation strategy
Boston firm to build portfolio of 8-12 biotechs with $350M second fund
BioCentury | Jan 12, 2021
Politics, Policy & Law
COVID accountability, Biden’s bidding & start-up season: a BioCentury podcast
Deals and venture rounds are being unveiled in droves as the J.P. Morgan conference began Monday, but last week’s events in the U.S. capital and the ongoing pandemic have expanded the list of
BioCentury | Jan 8, 2021
Emerging Company Profile
Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer
Emerging Company Profile: Myeloid launches with programmed monocyte cell therapies for cancer
Items per page:
1 - 10 of 10